ライフサイエンスコーパス: osteoporosis

1 used in the treatment of bone malignancy or osteoporosis.

2 fic treatment option for WNT1-related OI and osteoporosis.

3 ide with risedronate in patients with severe osteoporosis.

4 en include increased risks of depression and osteoporosis.

5 s an effective strategy for the treatment of osteoporosis.

6 ificantly contributes to the pathogenesis of osteoporosis.

7 L-induced bone loss in three mouse models of osteoporosis.

8 therapy currently approved for treatment of osteoporosis.

9 , kidney failure, neuronal degeneration, and osteoporosis.

10 c factor and may play a role in pathological osteoporosis.

11 associated with the ageing process including osteoporosis.

12 to influence the clinical management of male osteoporosis.

13 be useful agents for preventing and treating osteoporosis.

14 have been associated with the progression of osteoporosis.

15 f drugs frequently used for the treatment of osteoporosis.

16 udes men and women with low bone density and osteoporosis.

17 in an estrogen-deficient mammalian model for osteoporosis.

18 ent is strongly positive for most women with osteoporosis.

19 onsidered for novel strategies to counteract osteoporosis.

20 sequence data of Framingham Heart Study for osteoporosis.

21 as a therapeutic strategy for postmenopausal osteoporosis.

22 dditional loci with biological functions for osteoporosis.

23 ns, including osteoclast differentiation and osteoporosis.

24 ht new treatment approaches for bone loss in osteoporosis.

25 or repurposing probiotics for the therapy of osteoporosis.

26 treatment of metabolic bone diseases such as osteoporosis.

27 pA may be useful in future efforts targeting osteoporosis.

28 uchenne muscular dystrophy for prevention of osteoporosis.

29 ow guidelines established for postmenopausal osteoporosis.

30 ture repair in rats with ovariectomy-induced osteoporosis.

31 ch as cardiovascular diseases, diabetes, and osteoporosis.

32 ty genes that are biologically meaningful to osteoporosis.

33 been associated with increased incidence of osteoporosis.

34 of bone pain, bone fractures, and new-onset osteoporosis.

35 ice, prednisolone treated CD1 mice developed osteoporosis.

36 he ovariectomy mouse model of postmenopausal osteoporosis.

37 usly and may be a new therapeutic target for osteoporosis.

38 rmone deficiency without previously reported osteoporosis.

39 ptive agent widely used for the treatment of osteoporosis.

40 in the past two decades in the management of osteoporosis.

41 ) may be a risk factor for bone fracture and osteoporosis.

42 of PTHLH was associated with postmenopausal osteoporosis.

43 peutic avenue for both muscular diseases and osteoporosis.

44 lthy and osteoporotic bone in a rat model of osteoporosis.

45 pha attenuated bone loss in a mouse model of osteoporosis.

46 ed and the potential protective role against osteoporosis.

47 last-related diseases such as postmenopausal osteoporosis.

48 eases, such as periprosthetic osteolysis and osteoporosis.

49 imply that XVR can improve the prediction of osteoporosis.

50 ndently associated with risk of lumbar spine osteoporosis.

51 15) were related to increased risk of lumbar osteoporosis.

52 d cachexia, preterm labor with delivery, and osteoporosis.

53 or the treatment of bone pathologies such as osteoporosis.

54 ns, and vitamin D malabsorption resulting in osteoporosis.

55 L-27 toward the treatment of post-menopausal osteoporosis.

56 ties for simultaneously treating obesity and osteoporosis.

57 strated to be involved in the development of osteoporosis.

58 levels/allelic variations and patients with osteoporosis.

59 mice from ovariectomy-induced (OVX-induced) osteoporosis.

60 er development for potential therapeutics in osteoporosis.

61 PTH, PTH(1-34), is used clinically to treat osteoporosis.

62 ome inhibitors in treating radiation-induced osteoporosis.

63 for the treatment of bone disorders such as osteoporosis.

64 reatment of low bone mass disorders, such as osteoporosis.

65 r the treatment of postmenopausal women with osteoporosis.

66 of skeletal diseases, such as osteopenia and osteoporosis.

67 acture in men who have clinically recognized osteoporosis.

68 herapeutic agent for focal radiation-induced osteoporosis.

69 ion, or whether it is a symptom/biomarker of osteoporosis.

70 o therapy, or to indicate possible secondary osteoporosis.

71 notypes including amyloidosis, alopecia, and osteoporosis.

72 vertebral fractures in women who have known osteoporosis.

73 potential therapeutic target for age-related osteoporosis.

74 m events were hypercholesterolemia (31%) and osteoporosis (19%).

75 joint replacement (6.02, 95% CI 4.66-7.77), osteoporosis (2.69, 95% CI 1.35-5.38), and anxiety (2.00

76 Fragility fractures caused by osteoporosis affect millions of people worldwide every y

77 We investigated the induction of osteoporosis after 8 months using 31 female merino land

78 is the use of trivalent lanthanides to treat osteoporosis, an emerging concept which has gathered sig

79 We enrolled 4093 postmenopausal women with osteoporosis and a fragility fracture and randomly assig

80 ey syndrome (HCS), a disease presenting with osteoporosis and acro-osteolysis.

81 common medications used for the treatment of osteoporosis and are also used to reduce metastases to b

82 eview focuses on newer methods of diagnosing osteoporosis and assessing fracture risk, as well as on

83 Diagnosis of osteoporosis and assessment of fracture risk were compar

84 SC transplantation, who are at high risk for osteoporosis and bone fractures after total body irradia

85 one mass, similar to cases of postmenopausal osteoporosis and cancerous osteolysis.

86 metabolite balance and completely prevented osteoporosis and changes in body composition that charac

87 ggest that NELL-1 deficiency plays a role in osteoporosis and demonstrate the potential utility of NE

88 eocyte therapies could hold promise as novel osteoporosis and disuse-induced bone loss treatments by

89 rnover markers are not used for diagnosis of osteoporosis and do not improve prediction of bone loss

90 However, management of osteoporosis and fracture prevention strategies are ofte

91 Vitamin C sufficiency may help prevent osteoporosis and fractures by mediating osteoclastogenes

92 Osteoporosis and fractures can worsen the quality of lif

93 Cheney syndrome, a disease characterized by osteoporosis and fractures, is associated with NOTCH2 mu

94 effort to find new and safer treatments for osteoporosis and frailty, we describe a novel series of

95 s the formation of calciprotein particles in osteoporosis and impaired calcium metabolisms.

96 f this novel combination in animal models of osteoporosis and in patients.

97 erostin increases bone mass in patients with osteoporosis and in preclinical animal models.

98 gracility predisposes contemporary humans to osteoporosis and increased fracture risk.

99 es, which affect immunity, inflammation, and osteoporosis and may impair lung function.

100 ssociation was found between the presence of osteoporosis and MCI (P <0.001) and between the presence

101 ovariectomized rats as a model of menopause-osteoporosis and menopause women.

102 dies are under clinical development to treat osteoporosis and metastatic bone disease.

103 A significant correlation was found between osteoporosis and missing teeth.

104 that PD patients are at higher risk for both osteoporosis and osteopenia compared with healthy contro

105 both contribute to the higher prevalence of osteoporosis and osteopenia in HIV-infected individuals.

106 ctive enriched milk powder in ovariectomized-osteoporosis and ovariectomized rats as a model of menop

107 growth and bone mass and increased risk for osteoporosis and pathologic fractures.

108 among postmenopausal females in the Buffalo Osteoporosis and Periodontal Disease Study (1997 to 2000

109 stmenopausal females enrolled in the Buffalo Osteoporosis and Periodontal Disease Study were followed

110 one health is critical to reduce the risk of osteoporosis and potentially debilitating consequences o

111 idely prescribed pharmacologic treatment for osteoporosis and reduce fracture risk in postmenopausal

112 assessment methods and medications targeting osteoporosis and related fractures, screening for fractu

113 as a standard strategy for the prevention of osteoporosis and related fractures.

114 Cathepsin K is a major drug target for osteoporosis and related-bone disorders.

115 altering PTH expression in diseases such as osteoporosis and secondary hyperparathyroidism.

116 a well-established mouse model of ageing and osteoporosis and show respiratory chain deficiency.

117 though there is a strong association between osteoporosis and skeletal muscle atrophy/dysfunction, th

118 ajor role for genetics in the development of osteoporosis and the variation in BMD.

119 kers and bone mineral density (BMD), risk of osteoporosis, and biomarkers of bone turnover.

120 hanical properties of young, treatment-naive osteoporosis, and bisphosphonate-treated cases were inve

121 a, epilepsy, cancer, dominant optic atrophy, osteoporosis, and Down's syndrome.

122 ents with breast cancer, causing osteopenia, osteoporosis, and fractures.

123 ith Hajdu-Cheney syndrome (HCS) present with osteoporosis, and HCS is associated with NOTCH2 mutation

124 Osteopenia, osteoporosis, and low bone mineral density are frequent

125 strokes), diabetes, chronic kidney disease, osteoporosis, and non-AIDS malignancies-and start co-med

126 with higher risk of cardiovascular disease, osteoporosis, and other conditions.

127 musculoskeletal disorders, such as myopathy, osteoporosis, and skeletal fractures; neuropsychiatric d

128 of bone cells is altered during early-stage osteoporosis, and that mechanobiological responses act t

129 The incidences of premature diabetes and osteoporosis are also substantially increased.

130 y, our data suggest that WNT1-related OI and osteoporosis are caused in part by decreased mTORC1-depe

131 ts Postmenopausal Osteoporosis Fractures and osteoporosis are common, particularly among older women,

132 Obesity and osteoporosis are two of the most common chronic disorder

133 asia, recurrent oral aphthae, short stature, osteoporosis, arthritis, neurologic problems, unexplaine

134 15, paired t test), and was able to identify osteoporosis (as defined by DXA), with 100% sensitivity

135 Osteoporosis (as evaluated by MCI) does not pose a risk

136 Inflammation may contribute to osteoporosis, as it does to many other chronic diseases.

137 ate the possibility of a correlation between osteoporosis, as measured by the mandibular cortical ind

138 er inflammation is etiologically relevant to osteoporosis, assessed from bone mineral density (BMD),

139 al cancer screening provides a comprehensive osteoporosis assessment without requiring changes in ima

140 bone mass, 6-month-old mutant mice developed osteoporosis, associated with an increase in osteoclasto

141 tly enriched or depleted in the promoters of osteoporosis-associated genes, including 4 transcription

142 In people with osteoporosis, bone turnover markers might be useful to a

143 ests a novel treatment strategy not only for osteoporosis, but also for multiple age-related comorbid

144 ed well against classifications for clinical osteoporosis by DXA (T score </=-2.5 at the hip or spine

145 reater than nine times the normal value, and osteoporosis by t scores.

146 were associated with BMD and postmenopausal osteoporosis by the two-stage strategy, and rs17013181 w

147 hown pleiotropic effects on bone tissue, and osteoporosis can aggravate periodontitis.

148 everal age-associated pathologies, including osteoporosis, cardiac fibrosis, and immunosenescence.

149 ers, individuals 1 and 2, who presented with osteoporosis, cataracts, sensorineural hearing loss, and

150 years +/- 13.8) were recruited from a single osteoporosis center.

151 skeletal development but undergo age-related osteoporosis, characterized by a reduction in osteoblast

152 or chronic conditions such as heart disease, osteoporosis, cognitive impairment, or some types of can

153 ebral compression fractures in patients with osteoporosis compared with that at magnetic resonance (M

154 and long-term deficiency has been linked to osteoporosis, diabetes and cancer.

155 r the treatment of chronic diseases, such as osteoporosis, diabetes and obesity.

156 ight into the pathophysiology of age-related osteoporosis, diabetes, and obesity.

157 Osteoporosis did not influence the prevalence of periodo

158 We note a watershed in osteoporosis drug discovery around the year 2000, when t

159 teoporotic patients and the long-term use of osteoporosis drugs is controversial.

160 No clinical trials have compared osteoporosis drugs with incident fractures as the primar

161 odifiable risk factor for bone fractures and osteoporosis, especially in low-income communities.

162 ion of growth and development, prevention of osteoporosis, first-line therapy for active disease, and

163 A state-transition microsimulation model of osteoporosis for postmenopausal women aged 55 years or o

164 Recommendation: The National Osteoporosis Foundation and American Society for Prevent

165 Methods: The National Osteoporosis Foundation and American Society for Prevent

166 disability weights proposed by the National Osteoporosis Foundation and did a series of sensitivity

167 Primary Funding Source: National Osteoporosis Foundation.

168 events (IRR, 2.43 [95% CI, 1.11-5.33]), and osteoporosis/fracture (IRR, 1.43 [95% CI, 1.03-2.01]).

169 with an increased risk of kidney disease and osteoporosis/fracture, this risk did not seem to be depe

170 Key Clinical Points Postmenopausal Osteoporosis Fractures and osteoporosis are common, part

171 ervative strategies could reduce the risk of osteoporosis/fractures among ICU survivors, as well as d

172 events, 41 and 14 kidney events, 230 and 121 osteoporosis/fractures, 82 and 94 diabetes mellitus, 114

173 ce of their genetic background on GC-induced osteoporosis (GIO).

174 in rats subjected to glucocorticoid-induced osteoporosis (GIOP) was assessed.

175 An association between atherosclerosis and osteoporosis has been reported in several studies.

176 rs are targets for existing drugs that treat osteoporosis, hypercalcaemia, Paget's disease, type II d

177 d with significantly greater odds of AEs for osteoporosis, hypertension, obesity, type 2 diabetes, ga

178 osteogenesis imperfecta (OI) and early-onset osteoporosis, identifying it as a key Wnt ligand in huma

179 detected in 2/8 case, osteopenia in 4/8 and osteoporosis in 2/8 patients.

180 Prevention of osteoporosis in adulthood begins with optimizing bone he

181 and lung cancer, lymphoma, Rett syndrome and osteoporosis in humans.

182 are associated with decreased bone mass and osteoporosis in humans.

183 KL/OPG ratio showed that the steroid-induced osteoporosis in its late progressive phase stimulates RA

184 s pool, and impaired osteogenesis as well as osteoporosis in later life.

185 drug therapy available for the treatment of osteoporosis in males and postmenopausal females.

186 ral density (BMD), or preventing or delaying osteoporosis in men with nonmetastatic prostate cancer.

187 t prevents neonatal death, liver damage, and osteoporosis in murine homocystinuria.

188 cked the osteoclast development in vitro and osteoporosis in OVX rat models.

189 lerosis and ischemia, which is shown by limb osteoporosis in patients with peripheral artery disease

190 Data for the optimum management of osteoporosis in patients with type 2 diabetes are scarce

191 dral ossification pathway genes with BMD and osteoporosis in postmenopausal Han Chinese women.

192 A) is cost-effective as a screening tool for osteoporosis in postmenopausal women.

193 T have been reported to be related to BMD or osteoporosis in the literature.

194 oalkyl substances, bone mineral density, and osteoporosis in the U.S. population in NHANES 2009-2010.

195 ) is the only current anabolic treatment for osteoporosis in the United States.

196 ow that mice deficient in SMURF2 have severe osteoporosis in vivo.

197 Osteoporosis in women was also associated with PFAS expo

198 n therapy or raloxifene for the treatment of osteoporosis in women.

199 he 5-year pharmacologic treatment period for osteoporosis in women.

200 ne loss following ovariectomy, which induces osteoporosis in WT females.

201 l reflux disease, thyroid disease, diabetes, osteoporosis) in the 12 months before diagnosis was defi

202 Osteoporosis induction in a sheep model by steroid admin

203 RANKL/OPG ratio correlation to the method of osteoporosis induction.

204 Osteoporosis is a common age-related disorder leading to

205 Osteoporosis is a common and debilitating bone disease t

206 Osteoporosis is a common disease diagnosed primarily by

207 Osteoporosis is a common skeletal disorder characterized

208 Osteoporosis is a common systemic skeletal disorder resu

209 Osteoporosis is a metabolic bone disorder associated wit

210 Male osteoporosis is a multifactorial disease, although it is

211 Osteoporosis is a prominent disorder affecting over 200

212 Transient osteoporosis is a relatively rare condition of unknown e

213 Osteoporosis is a systemic skeletal disorder characteriz

214 Osteoporosis is an enormous and growing public health pr

215 Osteoporosis is characterised by trabecular bone loss re

216 within the bone microenvironment to regulate osteoporosis is lacking.

217 The role of osteoblasts in diabetes-related osteoporosis is well acknowledged whereas the role of os

218 all of which will increase susceptibility to osteoporosis later in life.

219 lterations in bone tissue composition during osteoporosis likely disrupt the mechanical environment o

220 to adverse health outcomes, such as cancers, osteoporosis, lung, and cardiovascular disorders.

221 Bone degenerative pathologies like osteoporosis may be initiated by age-related shifts in a

222 ignificantly reduced mechanical integrity in osteoporosis may originate from porosity and alterations

223 ntibiotic use (OR, 1.17; 95% CI, 1.13-1.21), osteoporosis medication use (OR, 1.17; 95% CI, 1.08-1.26

224 Use of osteoporosis medication was higher at the end of year 1

225 To review the benefits and harms of osteoporosis medications (bisphosphonates, teriparatide,

226 ad at least 6 months of follow-up; evaluated osteoporosis medications among patients with CKD; and re

227 Effects of osteoporosis medications on BMD, fracture risk, and safe

228 g growth hormone therapy before the onset of osteoporosis might be optimum for bone health of adult p

229 rats were used as a menopause and menopause-osteoporosis model, respectively.

230 ovariectomized and dexamethasone treated rat osteoporosis model.

231 n the subgroup of patients with pre-existing osteoporosis (n=826; 0.97, 0.48-1.95).

232 tates in humans, such as caries of teeth and osteoporosis of bones.

233 One patient was diagnosed with transient osteoporosis of the hip and one with a stress fracture o

234 ure by biomechanical CT analysis--those with osteoporosis or "fragile bone strength"--agreed well aga

235 Imbalance will lead to conditions such as osteoporosis or hyperostosis.

236 ch as that of regeneration in the context of osteoporosis or irradiation.

237 ritis (OR = 1.36), diabetes (OR = 1.31), and osteoporosis (OR = 1.22).

238 onvulsant use (OR, 1.37; 95% CI, 1.31-1.43), osteoporosis (OR, 1.24; 95% CI, 1.14-1.34), male gender

239 ntitis was detected in 77.1% of females with osteoporosis/osteopenia (P >0.05).

240 evaluation were performed, and a history of osteoporosis/osteopenia was collected.

241 neral density analysis, three presented with osteoporosis/osteopenia.

242 bone of C57BL/6J ovariectomised mice and in osteoporosis patients.

243 na13 conditional knockout mice have a severe osteoporosis phenotype.

244 taurine rescued their growth retardation and osteoporosis phenotypes.

245 nit increase in serum PFOA, PFHxS, and PFNA, osteoporosis prevalence in women increased as follows: [

246 are postulated to influence bone quality and osteoporosis, principally via calcium-dependent alterati

247 Ovariectomized and ovariectomized-osteoporosis rats were used as a menopause and menopause

248 l the prioritized genes revealed several key osteoporosis related pathways, including Wnt signaling.

249 (i) long-term PM <2.5 mum (PM2.5) levels and osteoporosis-related fracture hospital admissions among

250 duce the primary outcome of incidence of all osteoporosis-related fractures (hazard ratio [HR] 0.94,

251 roportion of individuals who had one or more osteoporosis-related fractures over a 5-year period.

252 nalysis, risk of bone fracture admissions at osteoporosis-related sites was greater in areas with hig

253 is; however, its role in the pathogenesis of osteoporosis remains to be determined.

254 d a sensitivity and specificity in detecting osteoporosis, respectively, of 0.806 (SE 0.105; 95% CI,

255 Osteoporosis results from the imbalance between bone res

256 y of NELL-1 to mice with gonadectomy-induced osteoporosis results in improved bone mineral density.

257 ral density is a cost-effective strategy for osteoporosis screening in postmenopausal women and has t

258 lly characterized by acro-osteolysis, severe osteoporosis, short stature, neurological symptoms, card

259 th a better accuracy in excluding osteopenia/osteoporosis (specificity), since patients with a cortic

260 The Maternal Vitamin D Osteoporosis Study (MAVIDOS) was a multicentre, double-b

261 ation-based cohort, the Canadian Multicentre Osteoporosis Study, and tested the extent to which the 2

262 ex-matched control subjects from the Geelong Osteoporosis Study.

263 sociation between vascular calcification and osteoporosis suggests a link between bone and vascular d

264 de SNPs within or near previously identified osteoporosis susceptibility genes including ESR1 (6q25.1

265 rance less than 60 mL per min, treatment for osteoporosis, systemic steroids, or oestrogen-replacemen

266 ne (PTH), is the only approved treatment for osteoporosis that increases the rate of bone formation.

267 rtical-bone fragility is a common feature in osteoporosis that is linked to nonvertebral fractures.

268 ION: Among post-menopausal women with severe osteoporosis, the risk of new vertebral and clinical fra

269 there is little scientific evidence relating osteoporosis to marginal bone loss (MBL).

270 dations on treatment of low bone density and osteoporosis to prevent fractures in men and women.

271 current study reproduced the sheep model of osteoporosis to study the RANKL/OPG ratio correlation to

272 l density (BMD) in women with postmenopausal osteoporosis transitioning from bisphosphonate therapy.

273 Long-term safety and efficacy of osteoporosis treatment are important because of the chro

274 The benefit-to-risk ratio for osteoporosis treatment is strongly positive for most wom

275 6629 women aged 40 years or older initiating osteoporosis treatment with 2 consecutive dual-energy x-

276 identify women with a suboptimal response to osteoporosis treatment.

277 tigated for its benefits on bone healing and osteoporosis treatment; however, there is little informa

278 Unlike most chronic diseases, osteoporosis treatments are generally limited to a singl

279 Exposure to BPs and the use of other osteoporosis treatments during follow-up were determined

280 nificantly between patients with and without osteoporosis, urticaria pigmentosa or anaphylaxis, respe

281 umbar spine (LSBMD), and physician-diagnosed osteoporosis was assessed in 1,914 participants using da

282 Osteoporosis was evaluated using the MCI.

283 In women, the prevalence of osteoporosis was significantly higher in the highest ver

284 Osteoporosis was significantly more prevalent in those w

285 use, likely prescribed for the management of osteoporosis, was not associated with decreased breast c

286 To identify susceptibility genes for osteoporosis, we conducted an integrative analysis that

287 , postmenopausal women aged 60-90 years with osteoporosis were enrolled in 214 centres in North Ameri

288 isphosphonates are the frontline therapy for osteoporosis, which act by reducing bone remodelling, an

289 Bone diseases, such as osteoporosis, which are characterized by high rates of b

290 o future treatments for arteriosclerosis and osteoporosis, which are strongly associated with ageing

291 , we trace the evolution of drug therapy for osteoporosis, which began in the 1940s with the demonstr

292 ed estrogen deficiency increases the risk of osteoporosis, which can be effectively treated with the

293 The treatment of osteoporosis, which has the goals of fracture prevention

294 affinity show potential to prevent and treat osteoporosis while minimizing or eliminating carcinogeni

295 ith the occurrence of fragility fractures in osteoporosis, while improvements in structural and mecha

296 n for patients at high risk of osteopenia or osteoporosis who are not suitable for NtRTIs such as aba

297 ed >/=55 to </=90 years) with postmenopausal osteoporosis who had taken an oral bisphosphonate for at

298 In postmenopausal women with osteoporosis who were at high risk for fracture, romosoz

299 Forty-nine patients with osteoporosis who were suspected of having acute vertebra

300 ebral compression fractures in patients with osteoporosis, with good accordance with MR imaging when